WTO TRIPS Council (October 2020): European Union dismisses concerns that IPRs are a barrier to COVID-19 medicines and technologies

On Friday, 16 October 2020, the European Union provided the following perspectives during a three hour debate on the proposed waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19 co-sponsored by Eswatini, Kenya,… Continue Reading

WTO TRIPS Council (October 2020): South Africa issues clarion call urging support for TRIPS waiver proposal

On Friday, 16 October 2020, members of the World Trade Organization’s (WTO) TRIPS Council held a three hour debate on the proposal (IP/C/W/669) first tabled by India and South Africa for a waiver from certain provisions of the TRIPS Agreement… Continue Reading

KEI Sues HHS and the Army over Access to COVID-19 Contracts

On Friday October 16, 2020, KEI filed a lawsuit (under the Freedom of Information Act) against the Department of Health and Human Services (HHS) and the U.S. Army regarding requests for COVID-19 research and development and procurement contracts awarding hundreds… Continue Reading

COVID-19 Contracts

United States of America Below are links to copies of the contracts entered into by the US government for technologies to combat the COVID-19 pandemic. KEI is updating this page as we gain access to more contracts, and less redacted… Continue Reading

20 October 2020 – Save the Date – Government Funding of COVID-19 Vaccines and Other Medical Technologies

Government Funding of COVID-19 Vaccines and Other Medical Technologies DATE: Tuesday, 20 October 2020 TIME: EDT 9:00 to 10:30/UTC: 13:00 to 14:30/CEST: 15:00 to 16:30 CONVENER: Knowledge Ecology International (KEI) REGISTRATION: Please contact thiru [at] keionline.org BACKGROUND: On Tuesday, 20… Continue Reading

KEI panel on government funding of COVID drugs and vaccines at the Global Congress on Intellectual Property and the Public Interest

On October 5, 2020, KEI organized a panel about government funding of COVID-19 drugs and vaccines at the Global Congress on Intellectual Property and the Public Interest. Although the full Global Congress event was postponed to the year 2021, the… Continue Reading

Taxpayers are subsidizing 80 percent of Regeneron’s COVID-19 treatment’s R&D costs

Regeneron Pharmaceutical recently applied for Emergency Use Authorization of its investigational COVID-19 treatment, REGN-COV2, after Donald Trump said that it cured him of COVID-19, suggesting that Regeneron expects to cash in on the treatment. Taxpayers, however, are funding 80 percent… Continue Reading

KEI on Moderna’s Oct 8, 2020 Statement on Intellectual Property Matters during the COVID-19 Pandemic

(More on KEI’s work on coronavirus here: https://www.keionline.org/coronavirus, and on Moderna, here: https://www.keionline.org/moderna) Oct 8, 2020 Moderna’s statement on intellectual property matters during the COVID-19 pandemic is very good, and should be matched by every manufacturer of a therapeutic, vaccine… Continue Reading